Precigen, Inc.(PGEN)

Biotechnology · Germantown, MD

$7.62-0.13 (-1.61%)

Delayed quote: Oct 6, 2026, 2:25 PM EDT

EBITDA Yield: N/A

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T18:27:58.006Z.

Stored calculation inputs

Calculation as of: 2026-10-06T18:27:58.006Z.

Quote observation: 2026-10-06T18:25:07.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: -35,359,000
Quote market capitalization: 2,714,831,265
Total debt · period ending 2026-06-30: 98,345,000
Cash · period ending 2026-06-30: 16,329,000

FMP input reference: a0072c9ba75a446a7d1e5aacfaaadbcfff4c6e87cd9201c0b7532283a182addc

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

PGEN EBITDA Yield Metrics

EBITDA YIELD

N/A

PGEN Competitors' EBITDA Yield

PGEN

Precigen, Inc.

Current

Market Cap

$2.71B

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ACHC

Acadia Healthcare Company, Inc.

vs PGEN

Market Cap

$2.68B

EBITDA Yield

10.54%

TTM Avg

12.59%

3Y Avg

12.00%

5Y Avg

11.83%

AVAH

Aveanna Healthcare Holdings Inc.

vs PGEN

Market Cap

$2.66B

EBITDA Yield

7.62%

TTM Avg

8.87%

3Y Avg

7.02%

5Y Avg

6.94%

NEOG

Neogen Corporation

vs PGEN

Market Cap

$2.66B

EBITDA Yield

3.07%

TTM Avg

3.86%

3Y Avg

4.98%

5Y Avg

4.09%

MBX

MBX Biosciences, Inc. Common Stock

vs PGEN

Market Cap

$2.65B

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ATRC

AtriCure, Inc.

vs PGEN

Market Cap

$2.78B

EBITDA Yield

1.29%

TTM Avg

1.25%

3Y Avg

1.25%

5Y Avg

1.25%

TMDX

TransMedics Group, Inc.

vs PGEN

Market Cap

$2.80B

EBITDA Yield

3.70%

TTM Avg

2.99%

3Y Avg

2.18%

5Y Avg

2.18%

BEAM

Beam Therapeutics Inc.

vs PGEN

Market Cap

$2.62B

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DYN

Dyne Therapeutics, Inc.

vs PGEN

Market Cap

$2.86B

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PRVA

Privia Health Group, Inc.

vs PGEN

Market Cap

$2.57B

EBITDA Yield

N/A

TTM Avg

1.49%

3Y Avg

1.19%

5Y Avg

1.11%

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Precigen, Inc. (PGEN)	$2.71B	N/A	N/A	N/A	N/A
Acadia Healthcare Company, Inc. (ACHC)vs ›	$2.68B	10.54%	12.59%	12.00%	11.83%
Aveanna Healthcare Holdings Inc. (AVAH)vs ›	$2.66B	7.62%	8.87%	7.02%	6.94%
Neogen Corporation (NEOG)vs ›	$2.66B	3.07%	3.86%	4.98%	4.09%
MBX Biosciences, Inc. Common Stock (MBX)vs ›	$2.65B	N/A	N/A	N/A	N/A
AtriCure, Inc. (ATRC)vs ›	$2.78B	1.29%	1.25%	1.25%	1.25%
TransMedics Group, Inc. (TMDX)vs ›	$2.80B	3.70%	2.99%	2.18%	2.18%
Beam Therapeutics Inc. (BEAM)vs ›	$2.62B	N/A	N/A	N/A	N/A
Dyne Therapeutics, Inc. (DYN)vs ›	$2.86B	N/A	N/A	N/A	N/A
Privia Health Group, Inc. (PRVA)vs ›	$2.57B	N/A	1.49%	1.19%	1.11%

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

About Precigen, Inc.

Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies. Its extensive portfolio of proprietary platforms includes UltraVector, which leverages advanced DNA construction and computational modeling to engineer complex gene expression programs; mbIL15, a gene designed to enhance immune cell function; the non-viral Sleeping Beauty transposon/transposase system for genetic modification; and AttSite recombinases, tools for precise DNA recombination. Furthermore, Precigen utilizes its AdenoVerse platform, a library of engineered adenovectors for gene delivery and immunotherapy applications, alongside L. lactis, a food-grade bacterium. The company also provides RheoSwitch, an inducible gene switch system offering quantitative, dose-proportionate control over target protein expression's timing and amount; kill switches, designed to selectively eliminate cell therapies within the body; tissue-specific promoters for targeted gene expression; the UltraCAR-T platform for cancer treatment; and the ActoBiotics platform, which employs genetically modified bacteria to deliver proteins and peptides directly to mucosal sites. Precigen maintains strategic collaboration and license agreements with Alaunos Therapeutics, Inc., Ares Trading S.A., Oragenics, Inc., Castle Creek Biosciences, Inc., and Intrexon Energy Partners I and II, LLC. Established in 1998, Precigen, Inc., previously known as Intrexon Corporation, adopted its current name in January 2020 and is headquartered in Germantown, Maryland.

Germantown, MD

160 employees

www.precigen.com

Healthcare / Biotechnology